SecBot SecBot
DEFA14A ·Filed Apr 27, 2026

ALDX

Aldeyra Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed6mo ago SEC0001193125-26-182118
Proxy solicitation materials
Actionable Insight • Neutral

No immediate trading action warranted. Monitor the annual meeting outcome for any unexpected vote results, though all proposals are expected to pass. The non-binding say-on-pay vote could signal governance concerns if opposed by a significant minority.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
ALDX ▼ -1.27% at T+60d
NEUTRAL call -1.27% · α vs SPY -5.26% · entry $1.57 → $1.55
Entry = T+0 close
Apr 27, 2026
via day close
T+1d
-2.55%
call -2.55% · α -2.54%
$1.53
settled 6mo ago
T+5d
+3.18%
call +3.18% · α +1.49%
$1.62
settled 6mo ago
T+20d
+13.38%
call +13.38% · α +7.91%
$1.78
settled 5mo ago
T+60d
-1.27%
call -1.27% · α -5.26%
$1.55
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Aldeyra Therapeutics filed additional definitive proxy materials for its 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026. The proposals include the election of one Class III director nominee, ratification of BDO USA as auditor, and an advisory vote on executive compensation. The board recommends a vote 'For' all items. This filing is routine and carries no material financial or strategic impact.

Key Financial Metrics

Vote
director election
Meeting
2026-06-09
Seats Contested
0

Key Facts

  • Annual meeting set for June 9, 2026; vote deadline June 8, 2026.
  • Proposal 1: Elect Class III director Todd C. Brady, M.D., Ph.D.
  • Proposal 2: Ratify BDO USA, P.C. as independent auditor for FY2026.
  • Proposal 3: Non-binding advisory vote on named executive officer compensation.
  • Board recommends 'For' on all proposals.
  • Board member Martin J. Joyce previously notified he will not stand for re-election (8-K filed April 20, 2026).

Financial Impact

No financial impact from this filing.

Risk Factors

  • Low risk: unexpected shareholder dissent on executive compensation or auditor ratification.
  • Minimal risk: board composition shift with Joyce departure already disclosed.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-182118
Document: 0001193125-26-182118-index-headers.html0001193125-26-182118
Document: 0001193125-26-182118-index.html0001193125-26-182118
Document: 0001193125-26-182118.txt0001193125-26-182118
6 reports for ALDX
Performance horizon
67% Hit rate @ T+5 2 of 3 directional calls Went positive at some point 2 of 3 best @ T+5▲ +30.28%Mar 18, 2026
Filters
Rows
Reports for ALDX — sortable, filterable
TypeNow
Sep 29, 2026
28d ago
8-K
BULLISH ★ 7/10
$1.32 $0.9159▼ −30.61%▼ −32.56%$0.6326 (−52.08%)
Aug 16, 2026
10w ago
Institutional Cluster
BEARISH ★ 6/10
$1.56 $1.52▲ +2.56%▲ +1.37%$0.6326 (+59.45%)
Jul 30, 2026
12w ago
8-K
NEUTRAL ★ 2/10
$1.54 $1.55▲ +0.65%▼ −2.86%$0.6326 (−58.92%)
Apr 27, 2026
26w ago
DEFA14A
NEUTRAL ★ 2/10
$1.57 $1.62▲ +3.18%▲ +1.49%$0.6326 (−59.71%)
Apr 20, 2026
27w ago
8-K
NEUTRAL ★ 2/10
$1.68 $1.57▼ −6.55%▼ −7.63%$0.6326 (−62.35%)
Mar 18, 2026
31w ago
Insider Cluster
BULLISH ★ 5/10
$1.42 $1.85▲ +30.28%▲ +31.00%$0.6326 (−55.45%)
Showing 6 of 6

US Market Status

Market Open — Closes in 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026